X0202 SCHEDULE 13G/A 0001442891 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value per share 03/31/2026 0001674632 Beta Bionics, Inc. 08659B102 11 Hughes Suite 100 Irvine CA 92618 Rule 13d-1(b) Eventide Asset Management, LLC DE 5945488.00 0.00 5945488.00 0.00 5945488.00 N 13.4 IA Finny Kuruvilla, M.D., Ph. D. X1 0.00 5945488.00 0.00 5945488.00 5945488.00 N 13.4 HC IN Robin C. John X1 0.00 5945488.00 0.00 5945488.00 5945488.00 N 13.4 HC IN Beta Bionics, Inc. 11 Hughes, Suite 100, Irvine, CA 92618 (i) Eventide Asset Management, LLC ("Eventide") (ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla") (iii) Robin C. John ("John") Eventide, Kuruvilla and John: One International Place, Suite 4210 Boston, Massachusetts 02110 Eventide: Delaware Kuruvilla: United States John: United States N IA HC (i) Eventide: 5,945,488 (ii) Kuruvilla: 5,945,488 (iii) John: 5,945,488 (i) Eventide: 13.4% (ii) Kuruvilla: 13.4% (iii) John: 13.4% (1) Eventide: 5,945,488 (2) Kuruvilla: 0 (3) John: 0 (1) Eventide: 0 (2) Kuruvilla: 5,945,488 (3) John: 5,945,488 (1) Eventide: 5,945,488 (2) Kuruvilla: 0 (3) John: 0 (1) Eventide: 0 (2) Kuruvilla: 5,945,488 (3) John: 5,945,488 Y N As of March 31, 2026, Eventide Asset Management, LLC, a Delaware limited liability company located at One International Place, Suite 4210, Boston, Massachusetts 02110, is the beneficial owner of 5,945,488 shares of the Issuer's Common Stock by virtue of being the investment adviser to Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund which are registered investment companies, and Eventide separately managed accounts, (the "Accounts"). As of March 31, 2026, the Eventide Gilead Fund held 3,750,973 shares of the Issuer's Common Stock, representing 8.5% of the Issuer's outstanding Common Stock, the Eventide Healthcare & Life Sciences Fund held 2,052,176 shares of the Issuer's Common Stock, representing 4.6% of the Issuer's outstanding Common Stock, and Eventide's separately managed accounts held 142,339 shares of the Issuer's Common Stock, representing 0.3% of the Issuer's outstanding Common Stock, which together represents 13.4% of the Issuer's outstanding Common Stock. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities. EXHIBIT 1 - Filed Herewith Eventide Asset Management, LLC /s/ Peter J. Luiso 05/15/2026 Finny Kuruvilla, M.D., Ph. D. /s/ Finny Kuruvilla, M.D., Ph. D. 05/15/2026 Robin C. John /s/ Robin C. John 05/15/2026